Metastatic breast cancer is breast cancer that has spread from the breast to distant organs in the body. It is classified as stage 4, the most advanced stage, and it affects roughly 6% of women at the time of their initial diagnosis. The five-year relative survival rate for distant-stage breast cancer is 33.8%, a number that has been steadily improving as new treatments become available.
How It Differs From Early-Stage Breast Cancer
Breast cancer is staged from 0 to 4. Stage 0 means abnormal cells are contained within the milk ducts and haven’t invaded surrounding tissue. Stages 1 through 3 describe cancer that may have grown into nearby tissue or reached regional lymph nodes but hasn’t traveled to distant parts of the body. Stage 4, or metastatic breast cancer, means cancer cells have left the breast and nearby lymph nodes entirely and established new growths in other organs.
There are two paths to a metastatic diagnosis. About 5% to 10% of people are stage 4 from the very first diagnosis, a situation called “de novo” metastatic breast cancer. The rest develop metastatic disease months or years after being treated for an earlier stage. In one large study, roughly 27% of metastatic patients were de novo, while 73% had a recurrence, with nearly half of those recurring more than two years after their original treatment.
Where Breast Cancer Typically Spreads
Cancer cells travel through the bloodstream or the lymphatic system. Breast cancer usually reaches the lymph nodes first, particularly those in the armpit and under the collarbone. From there, the four most common destinations are bones, lungs, liver, and brain. In more than half of metastatic cases, bone is the first distant site affected.
The location of the spread matters because it shapes both symptoms and treatment. A person with bone-only metastasis has a very different experience from someone whose cancer has reached the brain, even though both are classified as stage 4.
Symptoms Based on Where It Spreads
Metastatic breast cancer can cause symptoms that seem unrelated to the breast, which is part of what makes it difficult to recognize. The symptoms depend almost entirely on which organ is involved.
- Bones: Persistent, worsening pain in the back, hips, or ribs. Bones weakened by cancer can fracture more easily than normal.
- Lungs: Shortness of breath, a chronic cough, or chest pain that doesn’t resolve.
- Liver: Nausea, loss of appetite, unexplained weight loss, abdominal swelling, or yellowing of the skin and eyes.
- Brain: Headaches (often worse in the morning), vision changes, dizziness, seizures, or difficulty with balance and coordination.
General symptoms like fatigue, unintentional weight loss, and persistent pain can also signal metastatic disease, especially in someone with a breast cancer history.
How a Metastatic Diagnosis Is Confirmed
If metastatic breast cancer is suspected, doctors use a combination of imaging and tissue sampling. Imaging typically includes some or all of the following: CT scans, bone scans, PET scans, and MRIs. Blood tests checking liver and kidney function can also flag abnormalities that point toward spread.
Imaging alone isn’t always enough. A biopsy of the suspected metastatic site confirms that the cells originated in the breast and reveals important biological details: whether the cancer is fueled by hormones (hormone receptor status), whether it overproduces a growth-promoting protein called HER2, or whether it falls into the harder-to-treat “triple-negative” category. These characteristics can actually change between the original tumor and the metastatic one, so re-testing matters. The results directly determine which treatments are most likely to work.
Treatment Goals: Managing, Not Curing
For the majority of people with metastatic breast cancer, treatment with the intent to cure is not possible. That sounds stark, but it doesn’t mean treatment is futile. The goal shifts to extending life and preserving quality of life by shrinking tumors, slowing growth, and managing symptoms. Many people live with metastatic breast cancer for years, cycling through different treatments as needed. Doctors increasingly describe it as a chronic disease that requires ongoing management rather than a single decisive intervention.
Palliative care, which focuses on symptom relief and emotional well-being, is part of the treatment plan from the start. This isn’t the same as hospice. Palliative care runs alongside active cancer treatment, addressing pain, nausea, anxiety, and other effects of both the disease and its therapies. It can also include targeted management for specific metastatic sites, such as treatments to strengthen bones or reduce swelling around brain tumors.
How Cancer Subtype Shapes Treatment
Not all metastatic breast cancers are treated the same way. The biological subtype of the tumor is arguably more important than the location of the spread when it comes to choosing a treatment strategy.
Hormone receptor-positive cancers, which make up the largest share, are often treated first with hormone-blocking therapy rather than chemotherapy. This approach tends to cause fewer side effects and can be very effective, particularly for people whose cancer hasn’t reached internal organs like the liver or lungs. Real-world data shows that roughly 60% of metastatic patients receive hormone therapy as their first-line treatment.
HER2-positive cancers are treated with drugs that specifically block the HER2 protein. Combining these targeted drugs with hormone therapy in patients whose tumors are both hormone receptor-positive and HER2-positive has shown strong results. Five-year survival in this group reached 47.5% with the combination, compared to 36.3% with chemotherapy alone. A newer class of drugs called antibody-drug conjugates, which deliver chemotherapy directly to HER2-carrying cancer cells while largely sparing healthy tissue, has expanded options further. One such drug received FDA approval in late 2025 for use in combination therapy for HER2-positive metastatic disease.
Triple-negative breast cancer, which lacks hormone receptors and HER2, has historically been the hardest subtype to treat because it doesn’t respond to hormone therapy or HER2-targeted drugs. Chemotherapy remains a mainstay, though immunotherapy and other targeted approaches have begun to improve outcomes for certain patients in this category.
What Living With It Looks Like
People with metastatic breast cancer typically stay on some form of treatment indefinitely. A treatment is continued as long as it keeps the cancer stable or shrinking and the side effects remain manageable. When a treatment stops working, the team switches to another option. It’s common for someone to go through several different treatment lines over the course of years.
Between and during treatments, regular imaging scans monitor whether the cancer is growing, stable, or responding. Blood work tracks organ function and can sometimes detect rising levels of proteins shed by cancer cells. This ongoing surveillance helps doctors catch changes early and adjust the plan before symptoms worsen.
The emotional weight of a metastatic diagnosis is significant. Living with the knowledge that treatment will be ongoing, navigating side effects, and managing uncertainty about the future are challenges that psychosocial support, peer communities, and mental health care can meaningfully help with. Many cancer centers now build these services into the standard treatment plan rather than offering them as an afterthought.